1. Home
  2. NRIX vs AHCO Comparison

NRIX vs AHCO Comparison

Compare NRIX & AHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • AHCO
  • Stock Information
  • Founded
  • NRIX 2009
  • AHCO N/A
  • Country
  • NRIX United States
  • AHCO United States
  • Employees
  • NRIX N/A
  • AHCO N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • AHCO Medical/Nursing Services
  • Sector
  • NRIX Health Care
  • AHCO Health Care
  • Exchange
  • NRIX Nasdaq
  • AHCO Nasdaq
  • Market Cap
  • NRIX 1.3B
  • AHCO 1.4B
  • IPO Year
  • NRIX 2020
  • AHCO N/A
  • Fundamental
  • Price
  • NRIX $22.53
  • AHCO $10.15
  • Analyst Decision
  • NRIX Strong Buy
  • AHCO Strong Buy
  • Analyst Count
  • NRIX 15
  • AHCO 5
  • Target Price
  • NRIX $29.33
  • AHCO $12.40
  • AVG Volume (30 Days)
  • NRIX 1.1M
  • AHCO 1.0M
  • Earning Date
  • NRIX 10-11-2024
  • AHCO 11-05-2024
  • Dividend Yield
  • NRIX N/A
  • AHCO N/A
  • EPS Growth
  • NRIX N/A
  • AHCO N/A
  • EPS
  • NRIX N/A
  • AHCO N/A
  • Revenue
  • NRIX $56,424,000.00
  • AHCO $3,262,564,000.00
  • Revenue This Year
  • NRIX N/A
  • AHCO $3.34
  • Revenue Next Year
  • NRIX $7.17
  • AHCO $3.48
  • P/E Ratio
  • NRIX N/A
  • AHCO N/A
  • Revenue Growth
  • NRIX N/A
  • AHCO 4.49
  • 52 Week Low
  • NRIX $5.65
  • AHCO $6.43
  • 52 Week High
  • NRIX $29.56
  • AHCO $11.90
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 36.80
  • AHCO 45.46
  • Support Level
  • NRIX $20.65
  • AHCO $9.33
  • Resistance Level
  • NRIX $23.09
  • AHCO $9.93
  • Average True Range (ATR)
  • NRIX 1.52
  • AHCO 0.59
  • MACD
  • NRIX -0.58
  • AHCO -0.04
  • Stochastic Oscillator
  • NRIX 14.03
  • AHCO 46.74

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

About AHCO AdaptHealth Corp.

AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.

Share on Social Networks: